Solventum (NYSE:SOLV) Stock Rating Lowered by Wall Street Zen

Solventum (NYSE:SOLV) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.

Other research analysts have also recently issued reports about the company. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. UBS Group reissued a “neutral” rating on shares of Solventum in a research report on Friday, November 21st. Piper Sandler upped their price objective on shares of Solventum from $94.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Jefferies Financial Group assumed coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $85.56.

Solventum Trading Down 1.1%

NYSE SOLV opened at $84.32 on Monday. Solventum has a 12-month low of $60.70 and a 12-month high of $86.81. The company has a fifty day simple moving average of $73.77 and a two-hundred day simple moving average of $73.66. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. The stock has a market cap of $14.63 billion, a P/E ratio of 9.71, a P/E/G ratio of 9.00 and a beta of 0.25.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business’s quarterly revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, analysts forecast that Solventum will post 6.58 earnings per share for the current year.

Solventum announced that its Board of Directors has initiated a share buyback program on Thursday, November 20th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 7.5% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Independent Franchise Partners LLP grew its position in shares of Solventum by 74.2% during the 2nd quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company’s stock valued at $769,098,000 after acquiring an additional 4,320,342 shares during the period. Norges Bank purchased a new position in Solventum during the second quarter worth approximately $140,495,000. Boston Partners grew its holdings in Solventum by 101.3% in the first quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after purchasing an additional 1,691,565 shares during the period. Vanguard Group Inc. grew its holdings in Solventum by 5.3% in the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after purchasing an additional 867,837 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Solventum in the third quarter valued at approximately $42,393,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.